Seneca Biopharmaceuticals, Inc. is focused on finding promising new science and developing a pipeline of biopharmaceuticals.

Seneca Biopharmaceuticals, Inc.

Seneca Therapeutics, Inc. | 450 followers on LinkedIn. Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients with solid cancers | Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus.  SVV-001 is already in Phase I/II and has a clinical safety record in humans.

Founder, President and Chief Scientific Officer at Seneca Therapeutics, Inc.

Paul Hallenbeck

Board Member, Finance Advisory Committee Member, Corporate Advisor

Mark Kerschner

Chief Executive Officer at Seneca Therapeutics, Inc.

James Hussey

Human Resources and Business Operations Manager at Seneca Therapeutics, Inc

Janice Ingram

Seneca Therapeutics, Inc.

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics, Presented at Oncolytic Virus Conference on December 13th

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics Presented at Oncolytic Virus Conference on December 13th https://buff.ly/41zd97x

Seneca Therapeutics CSO and President Dr Paul Hallenbeck will present on December 13 at the 5th Annual Oncolytic Virotherapy Summit 2023. The talk is titled "Assessing the Benefits and Challenges of Intravenous Delivery pf Oncolytic Viruses". His talk will include the characteristics needed to delivery multiple doses of oncolytic viruses. He will also share the latest updates regarding TEM8, ANTXR1 and SVV-001. #ANTXR1 #TEM8 #SVV001 #OVmultipleIV

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at World Vaccine Congress November 28, 2023 https://buff.ly/40YCmIb

Seneca Therapeutics to Present Talk at World Vaccine Congress titled "Facilitating multiple deliveries of therapeutics vaccines by exploiting natural methods of evading neutralizing immunity" Seneca Therapeutics has continued to discover new and important features of Seneca Valley Virus (SVV-001). Dr. Paul Hallenbeck, Chief Science Officer and President at Seneca Therapeutics is presenting at the World Vaccine Congress on November 28, 2023. The title of the presentation is “Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity”. Using Seneca Therapeutics patented SVV-001 Gene Library and DNA Launch technology, the company discovered several biologically active SVV-001 mutants which evade neutralizing antibodies from prior SVV-001 exposure. (SVV-nabev (neutralizing antibody evading)). Three mutants have been discovered which will permit six IV doses of SVV-001 over three months. Following the results of the Phase I/II trial with multiple IT dosing in SVV-001 sensitive neuroendocrine tumors, the company plans on bringing at least three SVV-nabev candidates for a single IV dosage regimen into the clinic. SVV-001 has been shown to be safe as a single IV dose demonstrating excellent cancer selectivity. SVV-001 single IV dosing also demonstrated preliminary monotherapy efficacy against neuroendocrine tumors. Seneca Therapeutics has two other approaches for administering multiple IV doses of SVV-001 in development. #multipleIVdeliveryofcancerviruses #senecatherapeutics #TEM8tumormarker #SVV001 #cancervirusbreakthrough

DNSSEC

Person Schema

Gravatar Profiles

COVID-19

Chief Executive Officer

Tom Hallam

Vice President Clinical Operations

Nick McCoy

Senior Vice President, Operations and Strategic Development

Robert McRae

Board of Directors

Cristina Csimma

Sr. Director, Corporate Strategy

Joie Bernard

Director of Operations

Sharon McBrayer

Accounting Manager

Sofia Cornell

J.D. Finley

Executive Vice President, Chief Technology Officer at Palisade Bio

John Rodenrys

Chief Medical Officer (NASDAQ: PALI)

Mitchell L. Jones

Founder, CTO and EVP

Chief Operating Officer

Interim CEO, CFO

Chief Medical Officer

California Public Companies With Less Than $1B in Revenue

California Therapeutics Companies

United States Public Companies With Less Than $1B in Revenue

Greater San Diego Area Companies With Less Than $500M in Revenue (Top 10K)

Palisade Bio is a clinical-stage biopharmaceutical company developing treatments for diseases of unmet medical need. They base these treatments on sound science and therapies with a decades-long history of safe and effective usage. The company's mission is to develop and commercialize novel therapeutics that target diseases resulting from a loss of gastrointestinal barrier integrity. 

The company was founded in 2011 and is headquartered in Carlsbad, California.

Post-IPO Debt - Palisade Bio

Post-IPO Equity - Palisade Bio

Yuma Regional Medical Center

Altium Capital

Carlsbad

California

United States

North America

Palisade Bio

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Palisade Bio secures European patent for IBD treatments

Palisade Bio Announces Successful Completion of First GMP

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio announces notice of allowance for Canadian patent on PALI-2108

Palisade Bio to Present at the Virtual Investor Pitch Conference

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

A microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis.

A prodrug in preclinical development for the treatment of fibro stenotic Crohn’s Disease.

A platform that uses the phosphodiesterase-4 (PDE4) enzyme as its first therapeutic target to deliver drugs locally in the GI tract, minimizing systemic exposure.

Canada

Singapore

Asia

Pakistan

HTML5

Google Tag Manager

Office 365

Vimeo

GoDaddy Premium DNS

Google Fonts

Google Analytics

jQuery

Microsoft Outlook

Adobe Flash

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:59 PM	286def0d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:59 PM	fd4ca1fc
crunchbase trigger	general	Nov 17, 2024 8:59 PM	9ddc4a70
crunchbase profile	general	Nov 17, 2024 9:04 PM	9e4c72a6
li profile	general	Nov 17, 2024 8:59 PM	fed09345
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	60fff1a0
peers	general	Nov 17, 2024 8:59 PM	089c1f91
news basic	general	Nov 17, 2024 8:59 PM	548b1e6e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SENE

COM:SENECABIO

Seneca Biopharmaceuticals, Inc.